Date Time
Gene therapy appears more cost effective than current treatments for severe hemophilia B
From left: Co-senior author Nickhill Bhakta, M.D., of St. Jude Global Pediatric Medicine; co-senior author Ulrike Reiss, M.D., of the St. Jude Department of Hematology; and first and corresponding author Nancy Bolous, M.D., of St. Jude Global Pediatric Medicine, provide research on the costs of hemophilia gene therapy now in development.
A St. Jude Children’s Research Hospital analysis found a major gap between the cost to manufacture and distribute hemophilia B gene therapy and the $2 million-plus price reportedly under consideration for hemophilia gene therapy now in development.
E-Mail
IMAGE: First author Diego Hijano, M.D., of the St. Jude Department of Infectious Diseases, studied how the COVID-19 vaccine reduced symptomatic and asymptomatic infections in employees. view more
Credit: St. Jude Children s Research Hospital
Vaccination dramatically reduced COVID-19 symptomatic and asymptomatic infections in St. Jude Children s Research Hospital employees compared with their unvaccinated peers, according to a research letter that appears today in the
Journal of the American Medical Association.
The study is among the first to show an association between COVID-19 vaccination and fewer asymptomatic infections. When the Pfizer-BioNTech BNT162b2 vaccine was authorized for use in the U.S., the vaccine was reported to be highly effective at preventing laboratory-confirmed COVID-19. Clinical trial data suggested that the two-dose regimen reduced symptomatic disease, including hospitalization and death. But an association with reduced asymptomatic i